Interventional Oncology http://www.cxvascular.com/in-interventional-oncology/in-interventional-oncology <h1 class="header1">Interventional Oncology News</h1> en BIBA Medical Ltd Wed, 17 Dec 2014 23:02:55 GMT http://blogs.law.harvard.edu/tech/rss 3360 Affino 5 RSS Generator webeditor@bibamedical.com CeloNova gets US FDA approval for clinical trial with Oncozene http://www.cxvascular.com/in-interventional-oncology/in-interventional-oncology/celonova-gets-us-fda-approval-for-clinical-trial-with-oncozene <div style="display:block;"> <div id="ImageThumb1" style="float:left;"><a href="http://www.cxvascular.com/in-interventional-oncology/in-interventional-oncology/celonova-gets-us-fda-approval-for-clinical-trial-with-oncozene"><img src="http://www.cxvascular.com/AcuCustom/Sitename/DAM/044/Oncozene_thumb_-_Copy.jpg" border="0" hspace="5" vspace="5" /></a></div> <div id="ItemTeaser1" style="float:left;"> CeloNova BioSciences has announced that the US FDA has granted approval to start an investigational device exemption (IDE) clinical trial for its Oncozene embolic microspheres, loaded with doxorubicin, a chemotherapy drug used in the treatment of hepatocellular carcinoma. </div> </div> Fri, 14 Nov 2014 11:18:00 +0000 http://www.cxvascular.com/in-interventional-oncology/in-interventional-oncology/celonova-gets-us-fda-approval-for-clinical-trial-with-oncozene Terumo Europe to create an Interventional Oncology division http://www.cxvascular.com/in-interventional-oncology/in-interventional-oncology/terumo-europe-to-create-an-interventional-oncology-division <div style="display:block;"> <div id="ItemTeaser2" style="float:left;"> Terumo Europe has announced the creation of an Interventional Oncology division that will be active as of 1 April 2015. The specialisation of the interventional oncology team will allow Terumo Europe to be more focused, and thus more efficient in this fast growing market, a press release from the company states. </div> </div> Tue, 04 Nov 2014 09:30:00 +0000 http://www.cxvascular.com/in-interventional-oncology/in-interventional-oncology/terumo-europe-to-create-an-interventional-oncology-division SIR-Spheres recommended in new oncology clinical guidelines for treatment of metastatic colorectal cancer http://www.cxvascular.com/in-interventional-oncology/in-interventional-oncology/sir-spheres-recommended-in-new-oncology-clinical-guidelines-for-treatment-of-metastatic-colorectal-cancer <div style="display:block;"> <div id="ImageThumb3" style="float:left;"><a href="http://www.cxvascular.com/in-interventional-oncology/in-interventional-oncology/sir-spheres-recommended-in-new-oncology-clinical-guidelines-for-treatment-of-metastatic-colorectal-cancer"><img src="http://www.cxvascular.com/AcuCustom/Sitename/DAM/042/Sirtex_Graphic_thumb1.jpg" border="0" hspace="5" vspace="5" /></a></div> <div id="ItemTeaser3" style="float:left;"> Newly published European Society for Medical Oncology (ESMO) clinical guidelines for the treatment of metastatic colorectal cancer endorse radioembolisation, specifically with yttrium-90 (Y90) resin microspheres, as a clinically proven technology to “prolong time to liver tumour progression” in patients who have failed to respond to available chemotherapy options. </div> </div> Tue, 30 Sep 2014 11:13:00 +0000 http://www.cxvascular.com/in-interventional-oncology/in-interventional-oncology/sir-spheres-recommended-in-new-oncology-clinical-guidelines-for-treatment-of-metastatic-colorectal-cancer Sirtex expands business into Brazil http://www.cxvascular.com/in-interventional-oncology/in-interventional-oncology/sirtex-expands-business-into-brazil <div style="display:block;"> <div id="ImageThumb4" style="float:left;"><a href="http://www.cxvascular.com/in-interventional-oncology/in-interventional-oncology/sirtex-expands-business-into-brazil"><img src="http://www.cxvascular.com/AcuCustom/Sitename/DAM/015/sirtex_thumb_Thumb.jpg" border="0" hspace="5" vspace="5" /></a></div> <div id="ItemTeaser4" style="float:left;"> Sirtex has announced the expansion of its business in Latin America. Sirtex’s SIR-Spheres microspheres are now available to treat inoperable liver tumours in Brazil. </div> </div> Tue, 09 Sep 2014 09:32:00 +0000 http://www.cxvascular.com/in-interventional-oncology/in-interventional-oncology/sirtex-expands-business-into-brazil First patient enrolled in global phase III OPTIMA study of ThermoDox in primary liver cancer http://www.cxvascular.com/in-interventional-oncology/in-interventional-oncology/first-patient-enrolled-in-global-phase-iii-optima-study-of-thermodox-in-primary-liver-cancer <div style="display:block;"> <div id="ItemTeaser5" style="float:left;"> Celsion Corporation has announced that the first patient has been enrolled in its pivotal phase III OPTIMA study of ThermoDox in combination with optimised radiofrequency ablation in patients with hepatocellular carcinoma. The first patient was treated at Kyungpook National University Hospital in South Korea. </div> </div> Fri, 05 Sep 2014 09:40:00 +0000 http://www.cxvascular.com/in-interventional-oncology/in-interventional-oncology/first-patient-enrolled-in-global-phase-iii-optima-study-of-thermodox-in-primary-liver-cancer